OSCR
Oscar Health, Inc.
OSCR has the edge over TCRX overall, supported by stronger fundamentals and lower modeled downside.
TCRX
TScan Therapeutics, Inc.
TCRX offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TCRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
TCRX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TCRX PE Valuation
TCRX has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TCRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect TCRX's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TCRX on earnings quality, reporting a profit while its opponent remains loss making.
TCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.88 | +$0.23 |
| Q2 2026 | -$0.91 | +$0.17 |
| Q1 2026 | -$0.96 | +$0.12 |
| Q4 2025 | -$1.00 | +$0.14 |
TCRX is still losing money, but far less than before: $0.88 per share over the past year, against $3.01 at its worst in early 2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TCRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over TCRX on profitability, with a higher operating margin.
TCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $586K | -77% |
| Q2 2026 | $1.1M | -66% |
| Q1 2026 | $982K | -55% |
| Q4 2025 | $2.6M | +286% |
| Q3 2025 | $2.5M | +139% |
| Q2 2025 | $3.1M | +474% |
| Q1 2025 | $2.2M | +284% |
| Q4 2024 | $665K | -91% |
TCRX's revenue has slid since its 2023 peak: $586,000 last quarter, down 77% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5637% | -4161 points |
| Q2 2026 | -2901% | -1645 points |
| Q1 2026 | -2967% | -1298 points |
| Q4 2025 | -929% | +4591 points |
| Q3 2025 | -1476% | +1634 points |
| Q2 2025 | -1257% | +5108 points |
| Q1 2025 | -1670% | +3873 points |
| Q4 2024 | -5521% | -5224 points |
TCRX's operating margin was −5637% last quarter, down 4161 points from the same quarter a year ago, near the bottom of its range since 2020.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TCRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
TCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.1M | +$6.8M |
| Q2 2026 | -$28M | +$6.5M |
| Q1 2026 | -$24.3M | +$14.8M |
| Q4 2025 | -$32.2M | -$3.9M |
| Q3 2025 | -$33.9M | -$4.6M |
| Q2 2025 | -$34.5M | -$7.5M |
| Q1 2025 | -$39.1M | -$9.1M |
| Q4 2024 | -$28.3M | -$4.1M |
TCRX has burned cash in almost every quarter: −$112M over the past year, against −$136M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +77.1K shares |
| 1 year | +0.1% | +190K shares |
| 3 years | +175% | +82.8M shares |
| 5 years | +443% | +106M shares |
TCRX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TCRX Net Leverage
TCRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.3 | Oversold |
| Stochastic | 1.3 | Oversold |
TCRX's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TCRX PE vs Healthcare Sector
TCRX has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over TCRX on trend strength, trading above more of its moving averages.
TCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.23 | 26% below |
| 20 week MA | $0.53 | 68% below |
| 50 week MA | $0.85 | 80% below |
| 100 week MA | $1.34 | 87% below |
| 200 week MA | $3.02 | 94% below |
TCRX is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TCRX on returns for 2026, with the stronger performance.
TCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.5 | $4.86 | -54% |
| 2022 | $4.86 | $1.51 | -69% |
| 2023 | $1.51 | $5.83 | +286% |
| 2024 | $5.83 | $3.06 | -48% |
| 2025 | $3.06 | $1.06 | -65% |
| 2026 YTD | $1.06 | $0.17 | -84% |
TCRX's yearly returns have swung widely, from +286% in 2023 to −69% in 2022. It's down 84% so far in 2026.